We are live on ! Find out more
CTMX icon

CytomX Therapeutics
CTMX

90 hedge funds and large institutions have $343M invested in CytomX Therapeutics in 2017 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 42 increasing their positions, 14 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 14

27% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 15

7.76% more ownership

Funds ownership: 52.39% → 60.15% (+7.8%)

5% more funds holding

Funds holding: 86 → 90 (+4)

3% more capital invested

Capital invested by funds: $332M → $343M (+$11.1M)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
90
Holders Change
+4
Holders Change %
+4.65%
% of All Funds
2.24%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.07%
New
19
Increased
42
Reduced
14
Closed
15
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$12.1M
2
NI
Numeric Investors
Massachusetts
+$9.46M
3
BI
BVF Inc
California
+$3.35M
4
Renaissance Technologies
Renaissance Technologies
New York
+$2.65M
5
State Street
State Street
Massachusetts
+$2.49M

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$2.81M
2
PA
Perceptive Advisors
New York
-$2.11M
3
MBT
Montecito Bank & Trust
California
-$1.78M
4
PAG
Private Advisor Group
New Jersey
-$1.46M
5
PI
Putnam Investments
Massachusetts
-$1.29M
Name Holding Trade Value Shares
Change 		Change in
Stake
FAM
76
Fred Alger Management
New York
$78K +$75.4K +5,000 New
Acadian Asset Management
77
Acadian Asset Management
Massachusetts
$64K +$62.3K +4,132 New
BNP Paribas Financial Markets
78
BNP Paribas Financial Markets
France
$50.8K +$45.8K +3,039 +1,266%
MCM
79
Manchester Capital Management
Vermont
$50K – – –
AIP
80
Ameritas Investment Partners
Nebraska
$40K +$14.5K +959 +60%
UBS Group
81
UBS Group
Switzerland
$39K -$7.91K -525 -17%
DADC
82
D.A. Davidson & Co
Montana
$38K – – –
Canada Life
83
Canada Life
Manitoba, Canada
$28K – – –
Fifth Third Bancorp
84
Fifth Third Bancorp
Ohio
$23K – – –
AIM
85
Acrospire Investment Management
Illinois
$10K -$12.1K -800 -56%
PCM
86
Prelude Capital Management
New York
$5K +$4.52K +300 New
MAM
87
Meeder Asset Management
Ohio
$4K – – –
AWMS
88
Advocacy Wealth Management Services
Georgia
$2K – – –
Royal Bank of Canada
89
Royal Bank of Canada
Ontario, Canada
$1K -$10.3K -682 -94%
Citigroup
90
Citigroup
New York
$1K -$5.76K -382 -84%
PI
91
Putnam Investments
Massachusetts
– -$1.29M -74,819 Closed
LCM
92
Landscape Capital Management
New Jersey
– -$1.23M -70,943 Closed
TI
93
Trexquant Investment
Connecticut
– -$1.05M -60,979 Closed
CLCM
94
Crawford Lake Capital Management
New Jersey
– -$604K -35,000 Closed
HCM
95
Highbridge Capital Management
New York
– -$598K -34,627 Closed
Prudential Financial
96
Prudential Financial
New Jersey
– -$485K -28,070 Closed
VKH
97
Virtu KCG Holdings
New York
– -$388K -22,465 Closed
HLA
98
Hamilton Lane Advisors
Pennsylvania
– -$366K -21,199 Closed
MF
99
Magnetar Financial
Illinois
– -$255K -14,773 Closed
Two Sigma Investments
100
Two Sigma Investments
New York
– -$238K -13,762 Closed
1 2 3
4
5

CTMX Hedge Fund Activity: Q2 2017 in Review

90 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q2 2017, worth a combined $343M — up 3.4% from $332M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new CTMX positions and 15 closed out — a net gain of 4 holders — while 42 added to existing stakes and 14 trimmed.

The largest buyer was BlackRock, adding an estimated $12.1M. The largest seller was Deerfield Management, cutting an estimated $2.81M.

  • 90 institutional investors held CytomX Therapeutics (CTMX) as of Q2 2017, up from 86 in Q1 2017.
  • Funds reported $343M of CytomX Therapeutics stock for Q2 2017, up 3.4% quarter-over-quarter.
  • 19 funds opened new CytomX Therapeutics positions in Q2 2017 and 15 closed out, a net change of +4 holders.
  • The largest CytomX Therapeutics buyer in Q2 2017 was BlackRock, an estimated $12.1M added.
  • The largest CytomX Therapeutics seller in Q2 2017 was Deerfield Management, an estimated $2.81M sold.

Based on aggregated 13F filings for Q2 2017.